A detailed history of Great Valley Advisor Group, Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Great Valley Advisor Group, Inc. holds 16,400 shares of BCRX stock, worth $122,836. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,400
Previous 16,400 -0.0%
Holding current value
$122,836
Previous $101,000 22.77%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 16, 2024

SELL
$4.13 - $6.79 $4,130 - $6,790
-1,000 Reduced 5.75%
16,400 $101,000
Q1 2024

May 03, 2024

BUY
$4.89 - $7.65 $5,379 - $8,415
1,100 Added 6.75%
17,400 $88,000
Q3 2023

Nov 06, 2023

BUY
$6.71 - $7.92 $28,182 - $33,264
4,200 Added 34.71%
16,300 $115,000
Q2 2023

Aug 10, 2023

BUY
$6.96 - $8.81 $12,528 - $15,858
1,800 Added 17.48%
12,100 $85,000
Q1 2023

May 02, 2023

BUY
$7.94 - $11.84 $81,782 - $121,952
10,300 New
10,300 $85,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.39B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Great Valley Advisor Group, Inc. Portfolio

Follow Great Valley Advisor Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Valley Advisor Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Great Valley Advisor Group, Inc. with notifications on news.